Navigation Links
Monogram Energy, Inc. Acquires Triad Therapeutics, Inc.
Date:11/19/2009

FAIRFIELD, N.J., Nov. 19 /PRNewswire-FirstCall/ -- Monogram Energy, Inc. ("Monogram") (Pink Sheets: MGRN) announced today that it had completed the acquisition of Triad Therapeutics, Inc. ("Triad"), which was effective as of October 30, 2009. Under the terms of the Stock Purchase and Recapitalization Agreement, shareholders of Monogram acquired 100% of the outstanding shares of Triad in exchange for approximately 95% ownership to the Triad shareholders in the combined company. Monogram intends to apply to FINRA to change their name to Triad Therapeutics Holdings, Inc. and obtain a new ticker symbol.

Triad Therapeutics, a Joint Commission (JCAHO) accredited company, provides complex intravenous pharmaceuticals and supplies along with clinical nursing/pharmacy services to patients at home and in alternate care facilities. The specialized IV infusion services involve the administration of compounded medications needed in the treatment of a wide range of acute and chronic conditions including; infectious diseases, intractable pain, cardiovascular disease, multiple sclerosis and other neuromuscular disorders, nutritional disorders, and auto-immune diseases, dehydration, and IV catheter insertions with routine maintenance. The therapies associated with these conditions do not fit into the retail drug distribution model due to cost and the need for specialized pharmaceutical compounding, handling, and the need for extensive patient training by IV certified nursing professionals.

Forward-Looking Statements:

The statements which are not historical facts contained in this release are forward-looking statements that involve risks and uncertainties, including but not limited to, the effect of economic conditions, the impact of competition, the results of financing efforts, changes in consumers' preferences and trends. The words "estimate," "possible," and "seeking" and similar expressions identify forward-looking statements, which speak only to the date the statement was made. The Company undertakes no obligation to publicly update or revise any forward-looking statements, because of new information, future events, or otherwise. Future events and actual results may differ materially from those set forth herein, contemplated by, or underlying the forward-looking statements.

SOURCE Monogram Energy, Inc.


'/>"/>
SOURCE Monogram Energy, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Monogram Announces First Medicare Payment for Trofile(TM)
2. Monogram Biosciences to Present at The Lazard Capital Markets Fourth Annual Healthcare Conference
3. Monogram Biosciences Announces Immediate Availability of Enhanced Sensitivity Trofile(TM) HIV Tropism Assay
4. Monogram Biosciences Collaborates with Gilead Sciences for Elvitegravir Phase III Studies
5. Monogram Announces Commercial Availability of the HERmark(TM) Breast Cancer Assay
6. Monogram Announces 2008 Second Quarter Financial Results
7. Reliant Energy, Houston Texans Ahman Green and Matt Schaub Team to Hold News Conference, Book Signing to Raise Awareness about Autism
8. Study names 5 factors of social ills in energy, mining and logging communities
9. Healthcare and Education Building Markets Remain Particularly Strong as Energy, Materials and Commodity Costs Drive Construction Pricing Upward
10. DC policy panels on energy, environment, health care, aviation precede November election
11. Pennsylvania Governor Rendell Highlights Renewable Energy, Health Care Reform at Ag Progress Days
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... ... 23, 2017 , ... News Advisory/Interview Opportunity , After six years of advocacy, ... in Europe for public health and the environment and is calling on the United ... and the overwhelming support of European citizens, the European Union (EU) will, beginning next ...
(Date:3/23/2017)... ... March 23, 2017 , ... Ogden Clinic, the largest multi-specialty ... payment system, to expand its focus on patient care by providing an advanced ... , “At Ogden Clinic, we are working to become a different type of ...
(Date:3/23/2017)... ... March 23, 2017 , ... Vortex ... of “Profiling protein expression in circulating tumor cells using microfluidic western blotting” in ... of the Vortex technology to capture CTCs and a microfluidic single-CTC ...
(Date:3/22/2017)... ... 22, 2017 , ... Sam & Associates Insurance Agency, a ... related services to residents of the region, is embarking on a charity effort ... wild lands. , Endangered Species International is committed to ending the anthropogenic trends ...
(Date:3/22/2017)... (PRWEB) , ... March 22, 2017 , ... ... consuming and frustrating and this tool bypasses that. Healthcare facilities across the ... an opportunity to offer their clients and hospitals, across the country, an efficient ...
Breaking Medicine News(10 mins):
(Date:3/22/2017)... NEW YORK , March 22, 2017 ... ... cannabis market was worth an estimated $6.6 billion in 2016, and ... of 16% or reaching more than $24 billion by 2025. The ... 2025, or growing from $4.7 billion in 2016, to an estimated ...
(Date:3/22/2017)... 22, 2017 FinancialBuzz.com News Commentary ... rapidly due to the significant development and innovation in ... Market Research, the global electrophysiology market was worth $3.42 ... billion by 2022, with a GAGR of 13.4%. Electrophysiology ... diagnose abnormal heartbeats or arrhythmia. The report indicates that ...
(Date:3/22/2017)... MAPLE GROVE, Minn. , March 22, 2017   ... of Clomipramine Hydrochloride Capsules* USP, 25 mg, 50 mg and ... (clomipramine hydrochloride) Capsules USP. The clomipramine ... for the 12 months ending December 2016, according to IMS ... ...
Breaking Medicine Technology: